P38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients

Cancer

Volumn 118, Issue 20, 2012, Pages 5015-5025

  Planchard, David ^a   Camara Clayette, Valérie ^b   Dorvault, Nicolas ^a   Soria, Jean Charles ^a,c   Fouret, Pierre ^b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

cisplatin; ERCC1; lung cancer; never smokers; p38

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 11; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; EXCISION REPAIR CROSS COMPLEMENTING 1 GENE; FEMALE; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOKING HABIT;

CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; HUMANS; LUNG NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOKING;

EID: 84867335348     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27510     Document Type: Article

References (35)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123-132.
2. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537.
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957.
4. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004; 101: 13306-13311.
5. Sun S, Schiller JH, Gazdar AF,. Lung cancer in never smokers-a different disease. Nat Rev Cancer. 2007; 7: 778-790.
6. Cuenda A, Rousseau S,. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta. 2007; 1773: 1358-1375.
7. Wagner EF, Nebreda AR,. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009; 9: 537-549.
8. Das M, Jiang F, Sluss HK, et al. Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A. 2007; 104: 15759-15764.
9. Emerling BM, Platanias LC, Black E, Nebreda AR, Davis RJ, Chandel NS,. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol Cell Biol. 2005; 25: 4853-4862.
10. Hsieh YH, Wu TT, Huang CY, Hsieh YS, Hwang JM, Liu JY,. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res. 2007; 67: 4320-4327.
11. Junttila MR, Ala-Aho R, Jokilehto T, et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene. 2007; 26: 5267-5279.
12. Demuth T, Reavie LB, Rennert JL, et al. MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival. Mol Cancer Ther. 2007; 6: 1212-1222.
13. Matsuo Y, Amano S, Furuya M, et al. Involvement of p38alpha mitogen-activated protein kinase in lung metastasis of tumor cells. J Biol Chem. 2006; 281: 36767-36775.
14. Ventura JJ, Tenbaum S, Perdiguero E, et al. p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet. 2007; 39: 750-758.
15. Olson JM, Hallahan AR,. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004; 10: 125-129.
16. Mountzios G, Planchard D, Besse B, et al. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res. 2008; 14: 4096-4102.
17. Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002; 26: 558-564.
18. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006; 355: 983-991.
19. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G,. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-808.
20. Planchard D, Domont J, Taranchon E, et al. The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. Ann Oncol. 2009; 20: 1257-1263.
21. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002; 8: 2286-2291.
22. Young PR, McLaughlin MM, Kumar S, et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem. 1997; 272: 12116-12121.
23. Zarubin T, Han J,. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005; 15: 11-18.
24. Bachelor MA, Bowden GT,. UVA-mediated activation of signaling pathways involved in skin tumor promotion and progression. Semin Cancer Biol. 2004; 14: 131-138.
25. Xu K, Shu HK,. EGFR activation results in enhanced cyclooxygenase-2 expression through p38 mitogen-activated protein kinase-dependent activation of the Sp1/Sp3 transcription factors in human gliomas. Cancer Res. 2007; 67: 6121-6129.
26. Nebreda AR, Porras A,. p38 MAP kinases: beyond the stress response. Trends Biochem Sci. 2000; 25: 257-260.
27. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR,. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell. 2007; 11: 191-205.
28. Kennedy NJ, Cellurale C, Davis RJ,. A radical role for p38 MAPK in tumor initiation. Cancer Cell. 2007; 11: 101-103.
29. Wolfman JC, Palmby T, Der CJ, Wolfman A,. Cellular N-Ras promotes cell survival by downregulation of Jun N-terminal protein kinase and p38. Mol Cell Biol. 2002; 22: 1589-1606.
30. Qi X, Tang J, Pramanik R, et al. p38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem. 2004; 279: 22138-22144.
31. Tam IY, Chung LP, Suen WS, et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res. 2006; 12: 1647-1653.
32. Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res. 2009; 15: 5646-5661.
33. Li Q, Zhang L, Tsang B, Gardner K, Bostick-Bruton F, Reed E,. Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells. Cell Mol Life Sci. 1999; 55: 456-466.
34. Hayakawa J, Depatie C, Ohmichi M, Mercola D,. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J Biol Chem. 2003; 278: 20582-20592.
35. Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouet S,. GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells. Cancer Res. 2007; 67: 2114-2123.